Grifols 9-month profit up over four-fold, reduces Spain exposure
MADRID Oct 31 (Reuters) - Spanish pharmaceutical firm Grifols said its nine-month net profit had increased more than four times year-on-year on Wednesday, boosted by its acquisition of U.S. firm Talecris in June of 2011.
Grifols, the best performing stock on Spain's bluechip index over the past year, reported a net profit of 197 million euros ($255.66 million) and revenues of 1.96 billion euros, in line with analyst expectations.
The Barcelona-based company, a market leader in North America, said it continued to reduce exposure to its crisis-hit home market Spain, which now accounts for just 8 percent of its turnover. ($1 = 0.7705 euros) (Reporting by Clare Kane; Editing by Tracy Rucinski)
- U.S. Mega Millions lottery up to $400 million, 2nd-biggest ever
- Pope Francis named Time's Person of the Year |
- Uruguay becomes first country to legalize marijuana trade
- Thousands of South Africans line up to see Mandela lie in state |
- Atheists face death in 13 countries, global discrimination: study